8/18/2019 Relatively Poor Survival of Mucinous Ovarian Carcinoma in Advanced Stage: A Systematic Review and Meta-analysis | International…

We use cookies to improve our service and to tailor our content and advertising to you. More info

 
Home /  Archive /  Volume 27, Issue 4

Article Text Article menu 

Ovarian Cancer

Relatively Poor Survival of Mucinous Ovarian Carcinoma in PDF

Advanced Stage: A Systematic Review and Meta-analysis
Michiel Simons, MD*, Leon Massuger, MD, PhD†, Jolien Bruls, MD*, Johan Bulten, MD, PhD*, Steven
Teerenstra, PhD‡ and Iris Nagtegaal, MD, PhD*

Author affiliations

Abstract
Objective Overall, patients with mucinous ovarian carcinoma (MOC) are considered to have a better
prognosis compared with the whole group of nonmucinous carcinomas. However, some studies indicate
that patients with advanced-stage MOC might have a worse prognosis than those with advanced-stage
serous ovarian carcinoma (SOC). We carried out a systematic review and meta-analysis of the current
literature.

Materials and Methods A comprehensive literature search was carried out identifying 19 articles that
compare survival of patients with MOC and patients with SOC. Meta-analyses were performed for risk
ratio (RR) and hazard ratio (HR) for all International Federation of Gynecology and Obstetrics stages
together, as well as for early- and advanced-stage diseases separately.

Results Overall, patients with MOC showed a lower risk of dying within 5 years (RR, 0.67; 95% confidence
interval [CI], 0.64–0.69; n = 45 333) and a longer survival (HR, 0.66; 95% CI, 0.58–0.75; HR, 0.88; 95% CI,
0.78–0.98, for univariate and multivariate analyses, respectively; n = 5540) compared with those with
SOC. In contrast, in advanced-stage (International Federation of Gynecology and Obstetrics stages III and
IV) disease, patients with MOC have a higher risk of dying within 5 years (RR, 1.15; 95% CI, 1.13–1.17; n =
36 113) and a shorter survival (HR, 1.82; 95% CI, 1.71–1.94; n = 19 907).

Conclusions Patients with advanced-stage MOC have a significantly worse prognosis compared with
patients with SOC, whereas in early stage, the prognosis of patients with MOC is better.

http://dx.doi.org/10.1097/IGC.0000000000000932
https://ijgc.bmj.com/content/27/4/651.long 1/5
8/18/2019 Relatively Poor Survival of Mucinous Ovarian Carcinoma in Advanced Stage: A Systematic Review and Meta-analysis | International…

Request Permissions

Footnotes

The authors declare no conflicts of interest.

Request Permissions
If you wish to reuse any or all of this article please use
the link below which will take you to the Copyright
Clearance Center’s RightsLink service. You will be able
to get a quick price and instant permission to reuse the content in many different ways.

Request permissions

Copyright information: © 2017 by the International Gynecologic Cancer Society and the European
Society of Gynaecological Oncology.

Read the full text or download the PDF:

Buy this article (£30)

Subscribe

Log in

https://ijgc.bmj.com/content/27/4/651.long 2/5
8/18/2019 Relatively Poor Survival of Mucinous Ovarian Carcinoma in Advanced Stage: A Systematic Review and Meta-analysis | International…

Consultant in Clinical Oncology

Oxford, Oxfordshire £77,913 - £105,042
Consultant Clinical Oncologist to join our team of 54 Consultant Oncologists. The post specialises in Breast and Endocrine
malignancy
Recruiter: Oxford University Hospitals NHS Foundation Trust
Apply for this job

Consultant Obstetrician
Grampian
This is an Obstetric post with special interest in Fetal Medicine
Recruiter: NHS Grampian
Apply for this job

Consultant Clinical Oncologist

Swansea, Swansea (Abertawe) £75,881 - £98,515 per annum
Consultant Clinical Oncologist with special interest in colorectal and urological cancers required to join a team of clinical
and medical oncologists.
Recruiter: Swansea Bay University Health Board
Apply for this job

The Professorship of Surgical Oncology

Cambridge, Cambridgeshire
Standard professorial duties include teaching & research, contribution to clinical service delivery, examining, supervision &

We recommend
Survival of Patients With Mucinous Ovarian Carcinoma and Ovarian Metastases: A Population-
Based Cancer Registry Study
Michiel Simons et al., International Journal of Gynecologic Cancer, 2015

Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial
Ovarian Cancer
Helen J. Mackay et al., International Journal of Gynecologic Cancer, 2010

The Predictive Value of Circulating Tumor Cells in Ovarian Cancer: A Meta Analysis
Liqiong Zeng et al., International Journal of Gynecologic Cancer, 2017

Endometriosis-Associated Ovarian Cancer: Population Characteristics and Prognosis

Amilcar Barreta et al., International Journal of Gynecologic Cancer, 2018

Hydronephrosis as a Prognostic Indicator of Survival in Advanced Cervix Cancer

Tana S. Pradhan et al., International Journal of Gynecologic Cancer, 2011

LDH Serves as a Valuable Biomarker to Monitor Progress in RCC

PracticeUpdate, 2016

Postoperative Hormone Replacement Therapy in Epithelial Ovarian Cancer

https://ijgc.bmj.com/content/27/4/651.long 3/5
8/18/2019 Relatively Poor Survival of Mucinous Ovarian Carcinoma in Advanced Stage: A Systematic Review and Meta-analysis | International…

PracticeUpdate, 2015

Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers -

Vid

CONTENT

Latest content
Current issue
Archive
Podcasts
Videos
Twitter Journal Club

JOURNAL

About
Editorial board
Sign up for email alerts
Subscribe

AUTHORS

Instructions for authors

Submit an article
Open Access at BMJ

HELP

Contact us
Reprints
Permissions
Advertising
Feedback form
https://ijgc.bmj.com/content/27/4/651.long 4/5
8/18/2019 Relatively Poor Survival of Mucinous Ovarian Carcinoma in Advanced Stage: A Systematic Review and Meta-analysis | International…

   

Website Terms & Conditions

Privacy & Cookies
Contact BMJ

Online: ISSN 1525-1438 Print: ISSN 1048-891X

Copyright © 2019 BMJ Publishing Group Ltd, International Gynecologic Cancer Society, & European Society of
Gynaecological Oncology. All rights reserved.
京ICP备15042040号-3

https://ijgc.bmj.com/content/27/4/651.long 5/5